Four cardiac hormones eliminate up to two-thirds of human breast cancers in athymic mice

In Vivo. 2007 Nov-Dec;21(6):973-8.

Abstract

Background: Four cardiac hormones i.e. atrial natriuretic peptide (ANP), vessel dilator, long acting natriuretic peptide (LANP) and kaliuretic peptide have anticancer effects in vitro.

Materials and methods: These four cardiac hormones were infused subcutaneously for 28 days with weekly fresh hormones at 3 nM min(-1) kg(-1) body weight in athymic mice bearing human breast adenocarcinomas.

Results: Vessel dilator, LANP, kaliuretic peptide and ANP eliminated 67%, 50%, 67% and 33% of the HTB-132 human breast adenocarcinomas. LANP eliminated 100% and vessel dilator 1/3 of CRL-2327 breast adenocarcinomas. There was no recurrence of the breast cancers in the primary site and no metastasis except in the ANP-treated group in one year post-treatment. The natriuretic peptide receptors-A and -C were decreased 50% and 31%, respectively, in metastatic versus primary ANP-treated breast adenocarcinomas.

Conclusion: Four cardiac hormones eliminate up to two-thirds of human breast adenocarcinomas in athymic mice.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Atrial Natriuretic Factor / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Cell Line, Tumor
  • Humans
  • Mice
  • Neoplasm Metastasis
  • Peptide Fragments / therapeutic use
  • Protein Precursors / therapeutic use*

Substances

  • Antineoplastic Agents
  • Peptide Fragments
  • Protein Precursors
  • atrial natriuretic factor precursor (79-98)
  • atrial natriuretic factor prohormone (31-67)
  • Atrial Natriuretic Factor